Maravai LifeSciences Holdings, Inc. (MRVI)
NASDAQ: MRVI · Real-Time Price · USD
7.54
-0.14 (-1.82%)
At close: Nov 13, 2026, 4:00 PM EST
7.41
-0.13 (-1.72%)
Pre-market: Nov 16, 2026, 8:12 AM EST
MRVI Revenue
Maravai LifeSciences Holdings had revenue of $45.85M in the quarter ending September 30, 2026, with 10.14% growth. This brings the company's total for the last twelve months to $213.00M, up 10.68% year-over-year. In the year 2025, Maravai LifeSciences Holdings had annual revenue of $185.74M, down -28.34%. That makes Maravai LifeSciences Holdings the 17,059th largest company in the world by revenue and 2,839th in the United States.
Revenue (ttm)
$213.00M
Revenue Growth
+10.68%
P/S Ratio
9.20
Revenue / Employee
$519,502
Employees
410
Market Cap
1.96B
Revenue by Segment
Fiscal year ended Dec 31, 2025 See the full MRVI breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 185.74M | -73.44M | -28.34% |
| Dec 31, 2024 | 259.19M | -29.76M | -10.30% |
| Dec 31, 2023 | 288.95M | -594.06M | -67.28% |
| Dec 31, 2022 | 883.00M | 83.76M | 10.48% |
| Dec 31, 2021 | 799.24M | 515.14M | 181.33% |
| Dec 31, 2020 | 284.10M | 140.96M | 98.48% |
| Dec 31, 2019 | 143.14M | 19.31M | 15.59% |
| Dec 31, 2018 | 123.83M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Fortrea Holdings | 2.67B |
| Harmony Biosciences Holdings | 989.36M |
| Agios Pharmaceuticals | 140.84M |
| Septerna | 96.27M |
| Recursion Pharmaceuticals | 68.23M |
| Maze Therapeutics | 20.00M |
| Zenas BioPharma | 11.00M |
MRVI News
- 3 days ago - Maravai LifeSciences Holdings Transcript: Stifel 2026 Healthcare Conference 2026 - Transcripts
- 4 days ago - KeyBanc upgrades Maravai to Overweight on midterm election results - TheFly
- 4 days ago - Maravai Lifesciences upgraded to Overweight from Sector Weight at KeyBanc - TheFly
- 10 days ago - Maravai Lifesciences price target raised to $10 from $7 at Craig-Hallum - TheFly
- 11 days ago - Maravai Lifesciences price target raised to $9.50 from $8 at Stifel - TheFly
- 11 days ago - Maravai LifeSciences Holdings Slides: Investor presentation - Filings
- 11 days ago - Maravai LifeSciences Holdings Earnings Call Transcript: Q3 2026 - Transcripts
- 11 days ago - Maravai LifeSciences Holdings Earnings release: Q3 2026 - Filings